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Introduction: Surgical site infection (SSI) after minor
skin excisions has a significant impact on patient
morbidity and healthcare resources. Skin antisepsis prior
to surgical incision is used to prevent SSI, and is
performed routinely worldwide. However, in spite of the
routine use of skin antisepsis, there is no consensus
regarding which antiseptic agents are most effective. The
AVALANCHE trial will compare Aqueous Versus Alcoholic
Antisepsis with Chlorhexidine for Skin Excisions.
Methods and analysis: The study design is a
prospective, randomised controlled trial (RCT) with the
aim of investigating the impact of two different antiseptic
preparations on the incidence of superficial SSI in patients
undergoing minor skin excisions. The intervention of
0.5% chlorhexidine gluconate (CHG) in 70% alcohol will
be compared with that of 0.5% CHG in aqueous solution.
The trial will be conducted in four Australian general
practices over a 9-month period, with 920 participants to
be recruited. Consecutive patients presenting for minor
skin excisions will be eligible to participate. Randomisation
will be on the level of the patient. The primary outcome is
superficial SSI in the first 30 days following the excision.
Secondary outcomes will be adverse effects, including
anaphylaxis, skin irritation, contact dermatitis and rash
and patterns of antibiotic resistance.
Ethics and dissemination: The study has been
approved by the James Cook University Human Research
Ethics Committee (HREC). Findings will be disseminated
in conference presentations and journals and through
online electronic media.
Discussion: RCTs conducted in general practice differ
from hospital-based projects in terms of feasibility,
pragmatism and funding. The success of this trial will be
cemented in the fact that the research question was
established by a group of general practitioners who
identified an interesting question which is relevant to their
clinical practice and not answered by current evidence.
Trial registration number: ACTRN12615001045505;
Pre-results.
BACKGROUND
It is a routine practice prior to surgery to
carry out preoperative cleansing of the skin
with antiseptic preparations at the site of sur-
gical incisions (preoperative skin antisep-
sis).1–3 The purpose of preoperative skin
antisepsis is to reduce the incidence of surgi-
cal site infection (SSI) by removing microor-
ganisms on the skin through a combination
of mechanical removal and chemical
killing.1 3 4 The incidence of SSI arising from
surgery in general practice is usually 1–3%,
but has been recorded at rates as high as
10%.5–8 The consequences of SSI include
pain and discomfort for patients, increased
healthcare-associated costs and temporarily
reduced occupational and recreational prod-
uctivity and functionality.1 3 4 9 As a result,
reducing the incidence of SSIs is in the inter-
est of all stakeholders in healthcare.
The most commonly used preoperative
skin antiseptic preparations are povidone
iodine (PVI) and chlorhexidine gluconate
(CHG). They are available in aqueous and
alcoholic preparations and in different
Strengths and limitations of this study
▪ Practical clinical question relevant to clinical
practice.
▪ Recruitment of clinicians and participants will be
very feasible.
▪ Independent outcome assessor will assess
photographs of all infections.
▪ Conduct of trial in general practice will provide
clinically relevant results to end-user.
▪ Diagnosis of infection has an element of
subjectivity.
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concentrations.1 3 4 PVI and CHG are effective against a
wide range of Gram-positive and Gram-negative bacteria,
viruses and fungi, though CHG has a more appreciable
residual antiseptic activity on the skin after
application.1 2 4
Surprisingly, despite the routine use of preoperative
skin antisepsis, there is no definitive scientific consen-
sus regarding which antiseptic preparation is most
effective in preventing SSI.1 4 9 There are even less
definitive data available for antisepsis prior to clean
surgery, which the Centre for Disease Control (CDC)
defines as ‘an uninfected operation in which no inflam-
mation is encountered and the respiratory, alimentary,
genital or uninfected urinary tract is not entered’
(CDC, 2011).10 Prior studies of wound infection after
minor surgery in general practice in the Mackay region
have shown an SSI rate of ∼9.5%—an incidence that is
much higher than expected based on published results
of similar cohorts in other regions of Australia and the
world.11–14 The reason for this high infection rate is
unclear, but may be related to the hot, humid environ-
ment or to patient behaviour in our rural setting. On
the one hand, this infection rate is suboptimal, as the
CDC suggests that an acceptable rate of SSI after clean
minor surgery is <5%.15 However, in settings where
there is a low risk of infection after clean surgery,
studies of over 5000 procedures may be required to
detect a clinically relevant difference in infection from
an intervention with statistical confidence, making such
trials unfeasible.16 Conversely, because of the high rate
of infection in our patient cohort and the high minor
surgery workload in rural general practice,17 a study of
skin antisepsis for the prevention of SSI in our setting
is highly feasible.
In general, the evidence base guiding appropriate
selection of antiseptic agents is poor. A landmark study
found 2% CHG in 70% isopropyl alcohol to be superior
to an aqueous solution of 10% PVI; however, as alcohol
is known to have significant antimicrobial properties,
this was likely to be an active treatment component in
this study.18 Most recent meta-analyses, including a
Cochrane review, concur that it is difficult to make con-
clusive statements about whether there are differences
in the efficacy of CHG and PVI1 2 9 and the latest guide-
line on surgical skin antisepsis released by the
Queensland Department of Health agrees with this pos-
ition.4 The Queensland Department of Health does,
however, endorse the use of alcoholic solutions in pref-
erence to aqueous preparations,4 and two recent
meta-analyses have asserted that there is some evidence
to suggest that alcoholic solutions may be more effective
than aqueous solutions.1 2 Nonetheless, they agree that
the marked heterogeneity in type and application of
antiseptic preparations between available studies hinders
direct comparisons between them.1 2 This, combined
with the overall low statistical power of almost all avail-
able studies, makes it difficult to draw firm conclusions
about the proposed superiority of alcoholic solutions.1 9
Previous research in the Mackay region6 7 19 20 and
recent interviews (personal communication) have
revealed that the majority of Mackay general practi-
tioners (GPs) use CHG in preference to PVI, one of the
reasons behind this being perceptions of ‘messiness’
and skin staining. Therefore, for practical reasons, our
team has chosen to examine the difference between
alcoholic and aqueous CHG, rather than comparing the
relative efficacy of CHG and PVI.
The aim of our study is to determine whether there is
a difference in the incidence of SSI after minor skin
excisions in general practice (clean surgery) when alco-
holic CHG is used for preoperative skin antisepsis in
comparison with aqueous CHG.
We hope this research will provide more authoritative
direction about skin antisepsis to clinicians carrying out
a clean surgery. If our research demonstrates a differ-
ence in efficacy between alcoholic and aqueous CHG, its
dissemination may lead a change in behaviour which
may serve to reduce overall incidence of SSI after minor
skin excisions in general practice in Australia.
METHODS AND ANALYSIS
Study centre
This study will be conducted in four private general
practices in Mackay, Queensland (latitude 21E8S).
Mackay is a rural centre with around 100 local GPs ser-
vicing a population of 112 798.21 The study team have
previously carried out a number of successful rando-
mised controlled trials (RCTs) on minor skin excisions
within the Mackay region.6 8 19 20
Study design
This is a prospective RCT comparing the intervention of
0.5% CHG in 70% alcohol with that of 0.5% aqueous
CHG surgical skin preparation for the prevention of SSI
following ‘minor skin excisions’—benign or malignant
skin lesions excised under local anaesthetic—conducted
in general practice. Data will be collected over a
9-month period. The study will be conducted in accord-
ance with the CONSORT statement.
Intervention
The intervention of surgical skin antisepsis with 0.5%
CHG in 70% alcohol will be compared with that of the
control group of 0.5% CHG aqueous solution. The 0.5%
concentration of CHG aligns with guidelines released by
the Queensland Centre for Healthcare Related Infection
Surveillance and Prevention.22 The 70% alcoholic con-
centration of CHG is standard for alcoholic preoperative
skin preparations.2 The antiseptic solutions will be pur-
chased from an independent supplier with research
funding.
Recruitment of study participants
Consecutive patients over the age of 18 with capacity to
give informed consent, who present to participating GP
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practices for minor skin excisions, will be invited to par-
ticipate. The practice nurses will be responsible for
recruitment. Many provisions have been developed to
assure informed consent. First, all eligible participants
will be provided with a participant information sheet
before giving written informed consent. In addition,
practice nurses, rather than practice GPs, will recruit
patients. This is intended to minimise the risk of per-
ceived coercion, as nurses are somewhat less responsible
for direct decisions regarding patient care than the
patient’s GP. Furthermore, all nurses involved in the trial
will receive formal training regarding appropriate con-
senting procedures.
Randomisation
In this prospective RCT, randomisation will be per-
formed at the level of the patient with an allocation
ratio of 1:1. The random sequence will be generated
from a computer-generated random number table.
Allocation concealment will be attained using sealed,
numbered, tamperproof opaque envelopes such that
neither the patient, nor the clinicians involved in their
care, will be aware of their allocation until after they
have consented to be a part of the trial, thereby mini-
mising selection and confounding bias. The research
team involved in the assessment or treatment of patients
will have no role in the assignment process. The patients
will be blinded to treatment allocation, although there
are differences in the alcoholic skin preparation which
are identifiable to the patient. Blinding of the operating
doctors to the assigned skin antiseptic is not feasible
given the differing smell of the two solutions. The prac-
tice nurse or doctor assessing outcomes will be blinded
to the treatment allocation, as will the practice nurse col-
lecting data and the investigator team.
Inclusion criteria
▸ All patients over the age of 18 undergoing minor skin
procedures at the participating practices during the
study period who:
– have the capacity to give informed consent;
– are able to return for removal of sutures.
▸ Patients who are not presenting for:
– excision of sebaceous cyst;
– suturing of lacerations;
– excisions not requiring sutures, such as shave
biopsies;
– punch biopsies;
– excisions on body sites where epinephrine is
contraindicated.
Exclusion criteria
▸ Allergy to alcohol or chlorhexidine;
▸ Evidence of infection at or adjacent to the operative
site;
▸ Current use of antibiotics;
▸ Clinical indication for antibiotic treatment following
excision (besides SSI);
▸ Periocular excisions;
▸ Patients with a primary language other than English
for which certified translation services for that lan-
guage are not available.
Surgical and wound protocol
A surgical and wound management protocol will stand-
ardise the management across the study arms. The
protocol is modelled on previous protocols used in
similar trials, as well as in international guide-
lines,6 8 10 19 20 and was developed in consultation with
participating doctors and nurses. As per this protocol,
skin antisepsis will be applied in a consistent manner for
the study arms—drapes, gloves, sutures, local anaesthetic
and dressings will be the same across all sites and post-
operative wound care processes will be identical, with all
patients receiving a standard set of verbal and written
postoperative wound care instructions.
Outcome measures
Primary outcome measure
The primary outcome measure is the incidence of post-
operative SSI occurring within 30 days of the procedure
(defined below). Patients’ wounds will be assessed for
evidence of SSI when they present for the removal of
sutures; at any other time, if they present for wound
review due to signs and/or symptoms of SSI, or oppor-
tunistically if they represent for any other reason.
Wound assessment will be carried out by doctors or
nurses at each general practice and the presence or
absence of SSI recorded. There will be standardised
in-house training regarding the definition of infection.
All infections will be photographed and assessed for
infection by a second blinded independent outcome
assessor to improve validity and reliability.
If patients are deemed to have an SSI, they will be
treated with antibiotics as clinically indicated, and as per
standard practice, all wounds with a purulent discharge
will be swabbed.
Secondary outcome measure
Secondary outcome measures will be:
1. Adverse reactions to the preoperative skin antiseptic
agent, manifesting as any one of
A. Anaphylaxis,
B. skin irritation or contact dermatitis,
C. rash.
2. Microbiology of infected wounds with a purulent dis-
charge, and any patterns of antibiotic resistance.
Definitions
Surgical site infection
SSI will be determined in accordance with a modified
version of the CDC definition for superficial SSI:
▸ Infection occurs within 30 days after the excision,
▸ Infection involves only skin or subcutaneous tissue of
the incision;
▸ At least one of the following:
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– Purulent drainage with or without laboratory con-
firmation from the superficial incision,
– At least one of the following signs or symptoms:
pain or tenderness, localised swelling, redness or
heat,
– Diagnosis of superficial SSI by the GP;
▸ Stitch abscesses, characterised by minimal inflamma-
tion and discharge confined to the points of suture
penetration, will not be included as SSIs.6 8 10
Data collection
Data will be primarily collected through the use of a
written spreadsheet which will be completed by practice
nurses. A member of the research team will visit prac-
tices on a fortnightly basis to audit the data collection.
Baseline data will be collected regarding patient
demographics, including age, sex, occupation and
smoking status, as well as comorbidities, such as diabetes
mellitus or peripheral vascular disease, and current rele-
vant medications, such as anticoagulants and immuno-
suppressants. Data will also be recorded regarding the
excision itself, such as the incision length, the suture
size and the type of excision performed (ie, simple, flap,
two-layer procedure). A body site map will be used to
record excision site and the histology of the lesion will
also be recorded. Each item of data has been chosen
based on data extracted from other trials on risk factors
for SSI.5–8
Sample size calculation
Our sample size was calculated on the basis of three pre-
vious studies of SSI in the Mackay region.6 19 20 These
studies used mostly aqueous chlorhexidine as surgical
antisepsis. Pooled analyses showed a weighted mean SSI
rate of 9.35%, which has been rounded up to 10% as
our predicted baseline infection rate.6 19 20 We decided
that an absolute reduction in the SSI rate of 5% (to 5%)
would be clinically significant. To reach this conclusion
with statistical confidence, a power in excess of 80% and
a significance level of 0.05, a total of 435 patients would
be required in the intervention group and 435 patients
in the control group, thus 870 in total.
Our previous similar trials6 8 19 20 have had a drop-out
rate of <5%, so we will enrol an additional 50 patients to
counter potential attrition, providing a final sample size
of 920.6 8 19 20
Data analysis
The primary analysis is an intention-to-treat analysis
including all participants who undergo randomisation.
The analysis will be performed taking the individual
person as the unit of analysis. All reported p values will
be two-tailed and for each analysis, p<0.05 will be consid-
ered statistically significant. The main analysis will follow
the intention-to-treat principle. Baseline data across
control and intervention groups will first be assessed for
marked differences. The incidence of SSI (the primary
dependent variable) in each of the two groups of the
trial will then be compared using Pearson’s χ2 test.
Multivariable logistic regression analysis will be applied
in case differences exist between intervention and
control groups at baseline and the analysis requires
adjustment for confounders. We will also carry out
sensitivity testing for lost to follow-up patients and per-
protocol analysis for non-compliers to assess for the pos-
sible effects of systematic biases on results.
Potential problems
On the basis of our previous studies, we feel that the
recruitment of adequate patient numbers is feasible;
however, if we fail to recruit patients, we will invite addi-
tional general practices to participate.
In our previous studies, we have found that assessing
for infection at the time of removal of sutures facilitates
a high rate of follow-up. Any patients not followed up
will be analysed on an intention-to-treat basis.
We have not planned to perform an interim analysis
as we feel that variation in antisepsis is a minor interven-
tion, and the outcome of SSI is usually a minor medical
issue which is treated with a course of antibiotics. An
interim analysis would further increase the required
sample size reducing the feasibility of our trial.
DISSEMINATION
This project is due for completion 1 year after the start
of data collection. The translation of important findings
to clinical practice will be facilitated through dissemin-
ation in conference presentations and journals as well as
electronic media. The researchers will also aim to
publish their findings on a range of Australian FOAM
(Free Open Access Meducation) websites to reach the
next generation of technology-savvy health professionals.
A written lay summary of the results will also be dis-
played at the participating general practices for the
information of study participants.
ETHICAL CONSIDERATIONS
We do not expect the intervention in this study to place
participants at any significant risk of harm, as we
hypothesise a lower incidence of SSI in the intervention
group due to the use of alcoholic CHG. In any case, SSI
is a minor condition which can be easily treated without
significant long-term sequelae. To assure privacy and
confidentiality, all data spreadsheets and consent forms
will be kept in a locked cupboard throughout the trial,
then transferred to a locked safe at the conclusion of
the trial, where they will be kept for 15 years. Patients
will be deidentified in all data collection.
DISCUSSION
Very few large RCTs are conducted in a primary care
setting.23 24 Difficulties have been reported in recruiting
patients and clinicians,25 and RCTs have been reported
as being methodologically and practically difficult to
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conduct in general practice.11 However, it is important
that clinical practice be informed by adequate primary
care evidence. Otherwise GPs, the end-user of the
research process, who attempt to practise evidence-based
medicine, may have flawed tools and the guidelines they
use may not be applicable to the patients they see.26 27
Funding for primary care research in Australia is very
limited, particularly compared with UK and the
Netherlands with only 2% of NHMRC grants awarded to
primary care research between 2000 and 2008.28
General practice-based research differs in many ways
from hospital-based research in issues of funding, feasi-
bility and pragmatism, and we have used our experience
from conducting previous successful trials in general
practice to inform the design and methods of the
present study.6 8 19 20 Our study will be conducted for
total funding of $20 000, which is similar to the cost of
our previous trials.
Skin excisions form a large proportion of the work-
load of Australian GPs17 and this is even greater in
Queensland, the state with the highest incidence of skin
cancer in the world.29 This effect is magnified in
regional towns such as Mackay, where there are no per-
manent dermatologists or plastic surgeons. Using a
research question that is relevant to our clinical situation
increases the feasibility of recruitment of patients
because of our high case load of patients presenting for
skin excisions.
Our research question is practical and clinically rele-
vant. Local clinicians do not use betadine antisepsis
because of perceptions of ‘messiness’ and skin staining.
Therefore, to be pragmatic, our team has chosen to
examine the difference between alcoholic and aqueous
CHG, rather than comparing the relative efficacy of
CHG and PVI. We have also found that using a clinically
relevant research question engages GPs and practice
nurses, and facilitates practitioner recruitment, as well as
increases the potential for translation into clinical
practice.30
Our surgical and wound management protocol was
developed in consultation with participating doctors and
practice nurses, which again increases the ownership
and practicality of the project. Occasionally, scientific
rigour may be compromised at the expense of pragma-
tism. For instance, in contrast to hospital-based research,
it is simply not practically or financially feasible to have
an independent outcome assessor assessing each wound
at each of the three geographically dispersed practices.
To compensate for this, infections will be photographed
and assessed for infection by a second independent and
blinded outcome assessor, who will reassess every wound.
It is also not feasible to have an independent
researcher to recruit patients. In our trial, practice
nurses will be responsible for recruitment. Many provi-
sions have been developed to assure informed consent.
This is intended to minimise the risk of perceived coer-
cion, as nurses are somewhat less responsible for direct
decisions regarding patient care than the patient’s GP.
The practice nurses are also responsible for data collec-
tion and are paid on a fee per service basis that compen-
sates them for their time. The study involves very little
additional work for the participating GPs—they are not
responsible for any data collection, and were only
required to have knowledge of the process involved to
answer any possible queries.
The trial will provide guidance to GPs regarding skin
antisepsis, and will inform current clinical guidelines
and healthcare worker education. Although our study is
conducted in a tropical rural setting and we are aware
that our baseline infection rate is comparably high,6 7
we have no reason to believe that any relative risk reduc-
tion detected will not be generalisable to other settings.
If we detect a measurable decrease in the incidence of
SSI with alcoholic CHG, this may result in a change in
clinical practice, with an increase in the use of alcoholic
CHG, which could reduce SSI rates following clean
surgery. As this is a pragmatic trial, the findings can
potentially be immediately translated into clinical
practice.
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